Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.

Garrett Vygantas


Dr. Garrett Vygantas joined Burrill & Company in 2006 as a member of the Venture Group and is involved in the sourcing, evaluating and structuring new investment opportunities across the life science spectrum. Garrett is also a member of the Burrill International Group. In 2007 he founded New-Bridge Pharmaceuticals and serves as President & interim CEO.  NewBridge is a Dubai-based specialty pharmaceutical company commercializing innovative therapies to treat chronic diseases of increasing incidence (diabetes, obesity, cardiovascular and cancer) in emerging markets of the Middle East, Africa, Turkey and Caspian regions. He serves on the Board of NewBridge and is a Board Observer on Nora Therapeutics, Ikano Therapeutics, ProteoGenix, and NanoVasc.

Before joining Burrill, Garrett was with Genentech’s Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of age-related macular degeneration. Garrett previously worked with the Health Care Investment Banking group at Cowen and in Business Development at EntreMed.


Garrett is a co-instructor at UCSF’s Center for BioEntrepreneurship’s “Idea to IPO” course and has advised in the formation of numerous biotech start-ups. Garrett completed his Transitional Residency at the University of Pennsylvania and holds MD & MBA degrees from Georgetown University as well as a BS in biochemistry from Boston College. He is a member of Kauffman Fellows Class 13.